Colorectal Cancer, Metabolic Disease
Conditions
Keywords
colorectal cancer, air pollution, metabolomics, intestinal flora
Brief summary
Colorectal cancer is one of the malignant tumours with high morbidity and mortality worldwide, posing a serious threat to human health. In recent years, the incidence of colorectal cancer has been on the rise with changes in lifestyle and dietary habits. Although some progress has been made in treatments such as surgery, chemotherapy and radiotherapy, however, the early diagnosis, prognosis assessment and personalised treatment of colorectal cancer still face great challenges. Therefore, it is of great academic value and practical significance to deeply explore the influencing factors of colorectal cancer occurrence, development and its prognosis, especially the research on environmental factors and metabolomics.
Detailed description
In this study, investigators collected clinical information, blood, urine and stool for ambient air pollution analysis, blood metabolomics analysis and stool macro-genetic sequencing by including patients from healthy control and colorectal cancer groups, respectively. Environmental factors, metabolomics and intestinal microbiota data were integrated and analysed to screen for indicators that play a key role in colorectal cancer development and construct a colorectal cancer prediction model.
Interventions
DIAGNOSTIC_TESTcolorectal cancer
Patients diagnosed with colorectal cancer by pathological biopsy.
DIAGNOSTIC_TESTcolorectal neoplasm
Patients diagnosed with colorectal adenoma confirmed by colonoscopy.
Sponsors
Dong Peng
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Healthy control group: * age ≥18 years old; * no history of malignant tumour; * willing to participate in this study and sign the informed consent form; * complete basic data. 2. Gastric cancer group: * age ≥18 years old; * patients diagnosed with gastric cancer by pathological biopsy before operation; * no chemotherapy, radiotherapy, targeted and immunotherapy before enrolment; * willing to participate in this study and sign the informed consent; complete clinical data.
Exclusion criteria
* patients with primary malignant tumours other than gastric cancer; * patients with serious cardiopulmonary insufficiency and other systemic diseases that affect the choice of treatment plan; * patients who are not suitable for enrolment as assessed by the investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of postoperative complications | From date of surgery until the date of first documented postoperative complication, assessed up to 2 months after surgery. | Surgical complications was defined as any postoperative complication occurring during the postoperative hospitalisation period. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | From date of diagnosis until the date of death from any cause or or loss to follow-up, whichever came first, assessed up to 60 months. | Overall survival was defined as time from date of diagnosis until the date of death from any cause or or loss to follow-up. |
Countries
China
Outcome results
None listed